MRK · News · 20260909N

Keytruda Patent Expiration Outlook

Merck & Co., Inc. · 2026-09-09 · Importance 64 · Surprise 42

Third-party reports identify the expected 2028 expiration of Merck’s Keytruda patent protection as a significant future competitive and revenue risk. The reports do not quantify the associated revenue impact or specify the relevant jurisdiction or patent litigation status. Analysts nevertheless continue to cite Keytruda’s importance to Merck’s outlook while maintaining generally positive ratings.

Key facts

• Merck & Co., Inc.'s Keytruda patent expiration is in 2028. source
• The news digest states Merck & Co., Inc. faces the impending patent expiration of Keytruda in 2028. source
• Analysts list the 2028 Keytruda patent expiration as a risk to Merck & Co., Inc. source
• An article in the digest highlights the importance of Keytruda to Merck & Co., Inc. and notes an upcoming patent expiration. source